MCID: SLV012
MIFTS: 51

Salivary Gland Adenoid Cystic Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases, Skin diseases, Endocrine diseases

Aliases & Classifications for Salivary Gland Adenoid Cystic Carcinoma

Aliases & Descriptions for Salivary Gland Adenoid Cystic Carcinoma:

Name: Salivary Gland Adenoid Cystic Carcinoma 12 52 14
Adenoid Cystic Carcinoma 12 50 69
Cylindroma 12 50
Adenoid Cystic Carcinoma of Salivary Gland 69
Carcinoma, Adenoid Cystic 42
Eccrine Dermal Cylindroma 69
Carcinoma Adenoid Cystic 52
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 50
Carcinoma, Cribriform 69
Cribriform Carcinoma 50
Cylindroma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4866
MeSH 42 D003528
NCIt 47 C2970
UMLS 69 C0010606

Summaries for Salivary Gland Adenoid Cystic Carcinoma

NIH Rare Diseases : 50 adenoid cystic carcinoma (acc) is a rare form of adenocarcinoma, which is cancer that begins in gladular tissues. acc most commonly arises in the head and neck, in various parts of the major and minor salivary glands including the palate, nasopharynx, lining of the mouth, voice box (larynx) or windpipe (trachea). it can also occur in the breast, uterus, or other locations in the body. early symptoms depend on the tumor's location and may include lumps under the lining of the mouth or facial skin; numbness in the mouth or face; difficulty swallowing; hoarseness; pain; or paralysis of a facial nerve. acc often has long periods with no growth followed by growth spurts; however, it can be aggressive in some people. acc spreads along nerves or through the bloodstream, and only spreads to the lymph nodes in about 5-10% of cases. the cause of acc is currently unknown. treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. last updated: 12/10/2014

MalaCards based summary : Salivary Gland Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma, is related to lung adenoid cystic carcinoma and cervical adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Salivary Gland Adenoid Cystic Carcinoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Pathways in cancer. The drugs Fentanyl and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, trachea and breast, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and growth/size/body region

Disease Ontology : 12 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Wikipedia : 71 Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Related Diseases for Salivary Gland Adenoid Cystic Carcinoma

Diseases related to Salivary Gland Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 lung adenoid cystic carcinoma 30.7 AQP1 BCL2 CCND1 CDH1 CTTN CYLD
2 cervical adenoid cystic carcinoma 12.3
3 maxillary sinus adenoid cystic carcinoma 12.3
4 lacrimal gland adenoid cystic carcinoma 12.3
5 esophageal adenoid cystic carcinoma 12.2
6 laryngeal adenoid cystic carcinoma 12.2
7 breast adenoid cystic carcinoma 12.2
8 bartholin's gland adenoid cystic carcinoma 12.2
9 prostate adenoid cystic carcinoma 12.1
10 trachea adenoid cystic carcinoma 12.1
11 cribriform carcinoma 12.1
12 ethmoid sinus adenoid cystic carcinoma 12.1
13 parotid gland adenoid cystic carcinoma 12.0
14 adenoid cystic carcinoma of the corpus uteri 12.0
15 malignant cylindroma 12.0
16 cutaneous adenocystic carcinoma 12.0
17 brooke-spiegler syndrome 11.9
18 adnexal spiradenoma/cylindroma of a sweat gland 11.8
19 poncet-spiegler's cylindroma 11.8
20 cylindromatosis, familial 11.8
21 lymph node adenoid cystic carcinoma 11.0
22 adenoiditis 10.9
23 pachyonychia congenita 3 10.8
24 pachyonychia congenita 4 10.8
25 pachyonychia congenita 1 10.8
26 pachyonychia congenita 2 10.8
27 ceruminous carcinoma 10.8
28 spiradenoma 10.3
29 male infertility 10.3 BCL2 CCND1
30 childhood brainstem astrocytoma 10.2 AQP1 BCL2
31 acute allergic sanguinous otitis media 10.2 BCL2 CCND1
32 larynx verrucous carcinoma 10.2 CDH1 RUNX3
33 extramedullary plasmacytoma 10.2 MKI67 PCNA
34 brachydactyly small stature face anomalies 10.1 MKI67 PCNA
35 uterine hypoplasia 10.1 KIT MKI67
36 ovary serous adenocarcinoma 10.1 KIT NOS2
37 popliteal pterygium syndrome, bartsocas-papas type 10.1 CCND1 KIT MKI67
38 malignant epithelial mesothelioma 10.1 CDH1 KIT
39 extraosseous ewing's sarcoma 10.1 CCND1 KIT PCNA
40 his bundle tachycardia 10.1 BCL2 CCND1 MKI67
41 statin toxicity 10.1 BCL2 CCND1 MKI67
42 endotheliitis 10.1
43 oro-mandibular-limb hypogenesis syndrome 10.1 CCND1 MKI67 PCNA
44 malignant pleural solitary fibrous tumor 10.1 CCND1 CDH1 KIT
45 ornithinemia 10.1 CCND1 CDH1 PCNA
46 bronchiolitis obliterans with obstructive pulmonary disease 10.1 CCND1 CDH1 MKI67
47 proctitis 10.1 CCND1 CDH1 KIT
48 nevoid hypermelanosis, linear and whorled 10.0 BCL2 CCND1 CDH1
49 breast malignant phyllodes tumor 10.0 CCND1 CDH1 MKI67
50 pustulosis palmaris et plantaris 10.0 KIT MKI67

Graphical network of the top 20 diseases related to Salivary Gland Adenoid Cystic Carcinoma:



Diseases related to Salivary Gland Adenoid Cystic Carcinoma

Symptoms & Phenotypes for Salivary Gland Adenoid Cystic Carcinoma

UMLS symptoms related to Salivary Gland Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CCND1 MKI67 PCNA

MGI Mouse Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.2 AQP1 BCL2 CCND1 CDH1 CTTN CYLD
2 endocrine/exocrine gland MP:0005379 10.18 NOS2 PCNA RUNX3 AQP1 BCL2 CCND1
3 cellular MP:0005384 10.16 BCL2 CCND1 CDH1 CTTN CYLD EN1
4 behavior/neurological MP:0005386 10.14 AQP1 BCL2 CCND1 CYLD EN1 KIT
5 cardiovascular system MP:0005385 10.13 AQP1 BCL2 CCND1 CDH1 CTTN EN1
6 hematopoietic system MP:0005397 10.13 AQP1 BCL2 CCND1 CTTN CYLD EN1
7 immune system MP:0005387 10.07 BCL2 CCND1 CDH1 CTTN CYLD EN1
8 homeostasis/metabolism MP:0005376 10.06 AQP1 BCL2 CCND1 CDH1 CYLD EN1
9 digestive/alimentary MP:0005381 10.04 BCL2 CCND1 CDH1 CYLD KIT NOS2
10 mortality/aging MP:0010768 10.03 AQP1 BCL2 CCND1 CDH1 CTTN CYLD
11 integument MP:0010771 9.92 RUNX3 BCL2 CCND1 CDH1 CYLD EN1
12 neoplasm MP:0002006 9.7 WIF1 BCL2 CCND1 CDH1 CYLD KIT
13 reproductive system MP:0005389 9.61 EN1 KIT NOS2 PCNA AQP1 BCL2
14 respiratory system MP:0005388 9.23 AQP1 BCL2 CCND1 CTTN CYLD KIT

Drugs & Therapeutics for Salivary Gland Adenoid Cystic Carcinoma

Drugs for Salivary Gland Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
4
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
5
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
6
Doxepin Approved Phase 3 1668-19-5 667477 667468
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
9 Alkylating Agents Phase 3,Phase 2,Phase 1
10 Liver Extracts Phase 3,Phase 2,Phase 1
11 Anti-Infective Agents Phase 2, Phase 3,Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
13 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
15 Mitomycins Phase 3
16 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
17 Porfiromycin Phase 3
18 Adjuvants, Anesthesia Phase 3
19 Analgesics Phase 3
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Central Nervous System Depressants Phase 3
25 Narcotics Phase 3
26 pancreatic polypeptide Phase 3,Phase 1
27 Peripheral Nervous System Agents Phase 3
28 Antifungal Agents Phase 2, Phase 3,Phase 1
29 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
30 Hormone Antagonists Phase 2, Phase 3
31 Hormones Phase 2, Phase 3,Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
33 Steroid Synthesis Inhibitors Phase 2, Phase 3
34 Autonomic Agents Phase 3
35 Cholinergic Agents Phase 3
36 Neurotransmitter Agents Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Appetite Stimulants Phase 3
39 Central Nervous System Stimulants Phase 3
40 Contraceptive Agents Phase 3
41 Contraceptives, Oral Phase 3
42
Megestrol Phase 3 3562-63-8 19090 3080587
43 Antimitotic Agents Phase 3,Phase 2,Phase 1
44 Antidepressive Agents Phase 3
45 Antidepressive Agents, Tricyclic Phase 3
46 Histamine Antagonists Phase 3
47
Histamine Phosphate Phase 3 51-74-1 65513
48 Psychotropic Drugs Phase 3
49 Cola Nutraceutical Phase 3,Phase 2,Phase 1
50
Indinavir Approved Phase 2 150378-17-9 5362440

Interventional clinical trials:

(show top 50) (show all 110)
id Name Status NCT ID Phase
1 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
4 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
5 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
6 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
7 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
8 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
9 Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors Not yet recruiting NCT02838602 Phase 3
10 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
11 Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT00180921 Phase 2
12 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Unknown status NCT00003489 Phase 2
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
14 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2
15 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00581360 Phase 2
16 Study of RAD001 in Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2
17 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2
18 Dovitinib in Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2
19 Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Completed NCT01524692 Phase 2
20 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2
21 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2
22 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2
23 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2
24 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2
25 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2
26 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
27 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
28 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
29 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
30 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2
31 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2
32 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
33 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2
34 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
35 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2
36 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2
37 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2
38 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2
39 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2
40 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2
41 Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Recruiting NCT03087019 Phase 2
42 A Study of Apatinib in Metastatic Adenoid Cystic Carcinoma of the Head and Neck Recruiting NCT02775370 Phase 2
43 Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Recruiting NCT01192087 Phase 1, Phase 2
44 Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma Recruiting NCT02859012 Phase 2
45 Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer Recruiting NCT03146650 Phase 2
46 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting NCT03172624 Phase 2
47 Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Recruiting NCT02857712 Phase 2
48 Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Recruiting NCT01586767 Phase 2
49 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2
50 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT02098538 Phase 2

Search NIH Clinical Center for Salivary Gland Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Salivary Gland Adenoid Cystic Carcinoma

Anatomical Context for Salivary Gland Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Salivary Gland Adenoid Cystic Carcinoma:

39
Salivary Gland, Trachea, Breast, Lung, Lymph Node, Skin, Brain

Publications for Salivary Gland Adenoid Cystic Carcinoma

Articles related to Salivary Gland Adenoid Cystic Carcinoma:

(show top 50) (show all 58)
id Title Authors Year
1
Downregulation of nucleophosmin expression inhibited proliferation and induced apoptosis in salivary gland adenoid cystic carcinoma. ( 27501253 )
2016
2
Carcinoma-Associated Fibroblasts Lead the Invasion of Salivary Gland Adenoid Cystic Carcinoma Cells by Creating an Invasive Track. ( 26954362 )
2016
3
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. ( 26862087 )
2016
4
Inhibitory effects of silibinin on proliferation and lung metastasis of human high metastasis cell line of salivary gland adenoid cystic carcinoma via autophagy induction. ( 27822066 )
2016
5
Type III TGF-I^ receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-I_B signaling. ( 26531330 )
2016
6
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. ( 27000157 )
2016
7
Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. ( 27212063 )
2016
8
Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. ( 26631070 )
2016
9
PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma. ( 27648129 )
2016
10
Salivary gland adenoid cystic carcinoma. ( 26214665 )
2015
11
MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. ( 26693056 )
2015
12
Role of hypoxia-inducible factor-1I+ and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma. ( 25997612 )
2015
13
Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. ( 26175943 )
2015
14
Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. ( 26405993 )
2015
15
Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. ( 25520866 )
2014
16
Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. ( 24493792 )
2014
17
A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro. ( 25065562 )
2014
18
Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. ( 25551195 )
2014
19
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma. ( 24510998 )
2014
20
High expression of SOX2 is associated with poor prognosis in patients with salivary gland adenoid cystic carcinoma. ( 24828201 )
2014
21
19-year oncologic outcomes and the benefit of elective neck dissection in salivary gland adenoid cystic carcinoma. ( 24170702 )
2013
22
Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. ( 22647764 )
2012
23
High expression of the autophagy gene Beclin-1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma. ( 22712799 )
2012
24
Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. ( 22580922 )
2012
25
Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma. ( 21800291 )
2012
26
Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. ( 21551254 )
2011
27
Unfavorable clinical implications for hypermethylation of RUNX3 in patients with salivary gland adenoid cystic carcinoma. ( 21567090 )
2011
28
Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoid cystic carcinoma. ( 21550270 )
2011
29
Maslinic acid induces apoptosis in salivary gland adenoid cystic carcinoma cells by Ca2+-evoked p38 signaling pathway. ( 21279332 )
2011
30
Critical regions and spreading of runt-related transcription factor-3 C-phosphate-G (CpG) island methylation in human salivary gland adenoid cystic carcinoma. ( 21658745 )
2011
31
Metastatic pleural effusion: a rare presentation of salivary gland adenoid cystic carcinoma. ( 21545072 )
2011
32
CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. ( 21692051 )
2011
33
RNAi knockdown of C-erbB2 expression inhibits salivary gland adenoid cystic carcinoma SACC-83 cell growth in vitro. ( 23554633 )
2010
34
[RUNX3 expression and its methylation of 5'-CpG island in salivary gland adenoid cystic carcinoma cell lines ACC-2, ACC-3 and ACC-M]. ( 21223819 )
2010
35
[Evolution pattern of the Runx3 gene 5'-CpG island methylation in human salivary gland adenoid cystic carcinoma]. ( 21223798 )
2010
36
[Effects of Ezrin gene on the proliferation and invasion activity of human salivary gland adenoid cystic carcinoma]. ( 19575999 )
2009
37
Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. ( 18844240 )
2009
38
Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. ( 19688981 )
2009
39
NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. ( 19317804 )
2009
40
Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. ( 19589718 )
2009
41
Survival from salivary glands adenoid cystic carcinoma in European populations. ( 19095489 )
2009
42
Fine-needle aspiration biopsy as an auxiliary diagnostic tool on intraoral minor salivary gland adenoid cystic carcinoma. ( 18644520 )
2008
43
Coordinated expression of activated mitogen-activated protein kinases in salivary gland adenoid cystic carcinoma. ( 18657296 )
2008
44
Choroidal metastasis from submandibular salivary gland adenoid cystic carcinoma. ( 18254353 )
2008
45
Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. ( 18347813 )
2008
46
High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. ( 18326020 )
2008
47
DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. ( 17545515 )
2007
48
Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma. ( 17113340 )
2007
49
In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. ( 17543095 )
2007
50
SIKVAV, a laminin alpha1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathway. ( 17591960 )
2007

Variations for Salivary Gland Adenoid Cystic Carcinoma

ClinVar genetic disease variations for Salivary Gland Adenoid Cystic Carcinoma:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
2 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
3 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
5 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
6 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
7 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
8 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
9 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
10 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
11 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
12 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
13 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113

Cosmic variations for Salivary Gland Adenoid Cystic Carcinoma:

9 (show top 50) (show all 2094)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM51381 KIT salivary gland,face,carcinoma,adenoid cystic carcinoma c.2386A>G p.R796G 29
2 COSM1658882 ZNF507 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.34C>A p.P12T 28
3 COSM1659071 WASF2 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.15G>T p.T5T 28
4 COSM1658927 VWA8 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4027G>A p.E1343K 28
5 COSM1658946 VWA5B1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1486G>A p.V496I 28
6 COSM1658865 UNC80 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.305A>G p.Q102R 28
7 COSM1659040 UBTF salivary gland,NS,carcinoma,adenoid cystic carcinoma c.100A>C p.M34L 28
8 COSM1659017 UBTF salivary gland,NS,carcinoma,adenoid cystic carcinoma c.106A>T p.N36Y 28
9 COSM1659032 TXNRD3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.412A>G p.K138E 28
10 COSM1659053 TSC1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.3280G>T p.E1094* 28
11 COSM1659031 TRPV5 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.554A>G p.H185R 28
12 COSM1658989 TP53BP1 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.3854C>G p.T1285S 28
13 COSM43614 TP53 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.854A>C p.E285A 28
14 COSM1659070 TOMM34 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.555T>A p.P185P 28
15 COSM1658929 TOM1L2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.259G>A p.V87I 28
16 COSM34221 TIE1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.2050G>C p.A684P 28
17 COSM1659046 THRA salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.1162C>T p.R388W 28
18 COSM1658909 TFAP2D salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1306C>T p.R436W 28
19 COSM1659024 TBC1D31 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.845T>A p.L282Q 28
20 COSM1658982 TANGO6 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.352G>C p.G118R 28
21 COSM1658994 SUPT5H salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1094G>T p.R365L 28
22 COSM1658977 STXBP3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1275G>C p.R425S 28
23 COSM3863360 SPEN salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4207C>T p.R1403* 28
24 COSM1659068 SOX6 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.630T>C p.D210D 28
25 COSM1658954 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.2564G>A p.R855Q 28
26 COSM1659007 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.3476G>T p.R1159L 28
27 COSM1659023 SMARCA2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.4582T>A p.S1528T 28
28 COSM1658912 SLC26A2 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.1474C>T p.R492W 28
29 COSM1659026 SLC26A11 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1196T>C p.F399S 28
30 COSM1659093 SLC25A13 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.888G>A p.L296L 28
31 COSM1658992 SLC15A5 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.925C>G p.L309V 28
32 COSM1658944 SIK2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1387G>A p.E463K 28
33 COSM1658998 SF3B1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1873C>A p.R625S 28
34 COSM110695 SF3B1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1874G>T p.R625L 28
35 COSM1024904 SEC23B salivary gland,NS,carcinoma,adenoid cystic carcinoma c.5C>T p.A2V 28
36 COSM1658857 SCN11A salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1207T>C p.Y403H 28
37 COSM1658966 SCN10A salivary gland,NS,carcinoma,adenoid cystic carcinoma c.599C>T p.A200V 28
38 COSM1659012 SACS salivary gland,NS,carcinoma,adenoid cystic carcinoma c.6353C>A p.S2118Y 28
39 COSM1224460 RYR1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.5885C>T p.A1962V 28
40 COSM34768 RPS6KB2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.986G>A p.R329Q 28
41 COSM1659122 RPRD1B salivary gland,NS,carcinoma,adenoid cystic carcinoma c.192T>C p.N64N 28
42 COSM1659033 RNF38 salivary gland,mouth floor,carcinoma,adenoid cystic carcinoma c.623A>G p.H208R 28
43 COSM1658907 RALGAPA1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1222G>A p.V408I 28
44 COSM13036 PTPN11 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1520C>A p.T507K 28
45 COSM1658974 PTBP3 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1081C>G p.L361V 28
46 COSM1658975 PRKD2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1126C>G p.L376V 28
47 COSM1658781 PRDM16 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.677-1G>T p.? 28
48 COSM1658856 PQLC2 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.719A>C p.E240A 28
49 COSM1659034 POT1 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.725A>G p.Y242C 28
50 COSM1658879 PORCN salivary gland,NS,carcinoma,adenoid cystic carcinoma c.1073C>A p.T358N 28

Copy number variations for Salivary Gland Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma

Expression for Salivary Gland Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Salivary Gland Adenoid Cystic Carcinoma.

Pathways for Salivary Gland Adenoid Cystic Carcinoma

Pathways related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 BCL2 CCND1 CYLD NOS2 PCNA
2 12.15 BCL2 CCND1 CDH1 KIT NOS2
3 12.02 CYLD RUNX3 WIF1
4 11.97 CCND1 CTTN PCNA
5 11.95 CCND1 CDH1 NOS2
6 11.9 BCL2 CCND1 CDH1
7 11.84 CCND1 CDH1 NOS2
8 11.82 BCL2 CCND1 PCNA
9 11.75 AQP1 CCND1 NOS2
10 11.71 BCL2 CCND1 NOS2
11 11.56 BCL2 CCND1 NOS2
12 11.47 BCL2 CCND1 KIT
13 11.43 CDH1 KIT RUNX3
14
Show member pathways
11.38 BCL2 CCND1 CDH1 KIT PCNA
15 11.24 BCL2 CCND1 NOS2
16 11.14 CCND1 CTTN NOS2
17 11.04 CCND1 CDH1
18 10.93 CCND1 WIF1
19 10.65 CCND1 CDH1 CTTN

GO Terms for Salivary Gland Adenoid Cystic Carcinoma

Cellular components related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cortical cytoskeleton GO:0030863 8.62 CTTN NOS2

Biological processes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.62 AQP1 BCL2 CCND1 CDH1
2 focal adhesion assembly GO:0048041 9.46 BCL2 CTTN
3 melanocyte differentiation GO:0030318 9.43 BCL2 KIT
4 hemopoiesis GO:0030097 9.43 BCL2 KIT RUNX3
5 response to iron ion GO:0010039 9.4 BCL2 CCND1
6 developmental pigmentation GO:0048066 9.37 BCL2 KIT
7 regulation of developmental pigmentation GO:0048070 9.16 BCL2 KIT
8 lymphoid progenitor cell differentiation GO:0002320 8.96 BCL2 KIT
9 pigmentation GO:0043473 8.8 BCL2 EN1 KIT

Molecular functions related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.73 AQP1 BCL2 CCND1 CDH1 CTTN CYLD
2 proline-rich region binding GO:0070064 8.62 CCND1 CYLD

Sources for Salivary Gland Adenoid Cystic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....